21 August 2016
A new research funded by The Institute of Cancer Research (ICR), London, and Breast Cancer Now, could be used to develop tests for aggressive breast cancers, or even lead to a new treatment of breast cancer.
The study, published in the journal “Oncotarget” looked at breast cancer cells that were positive for the protein HER2 – the target for the drug Herceptin, which is found in around 20 per cent of tumours.
The ICR researchers developed a new image-based screening technique to identify cancer cells that didn’t stick to the protein laminin – which helps build scaffolding around cells to glue them together.
Women whose tumours had a specific pattern of activity in the two genes were three times as likely to die within 10 years as others with a different pattern of activity.
Scientists at The ICR spotted the pattern of gene activity among breast cancer cells with a particular ability to escape from the glue that normally holds them in place.
They believe the genes could play a key role in releasing cells from this glue – known as the extracellular matrix – so they can spread round the body.
They found that these cells tended to have high activity in a gene called F12 and low activity in another called STC2.
Study leader Dr. Paul Huang, Leader of the Protein Networks Team at the ICR said:
“Survival rates for breast cancer are now much higher than they were a few decades ago, but the disease remains deadly once it has spread round the body. Our study sheds light on how cancer cells unstick themselves from healthy tissue, and it could help pick out women at high risk of their cancer spreading and becoming fatal.
“We found that the activity of two genes which may help control how tightly cells are glued together is linked to breast cancer survival.
“If the results are confirmed in larger studies, it could give us a new way of assessing women’s survival chances in the clinic, and adjusting treatment accordingly.”
When the researchers analysed the same genes among 1,964 breast cancers, they found that this pattern of activity was strongly linked to survival.
Women whose tumours had high F12 activity and low STC2 activity had a 32 per cent chance of dying within 10 years, whereas those with low F12 activity and high STC2 activity had only a 10 per cent chance of dying.
Author: Dotun Obatuyi
My name is Dotun Obatuyi (Dotunoba), I hail from Osun state, a public health scientist (monitoring and evaluation specialist), my keen interests are researching, critiquing and writing feature articles on health, science and technology as well as issues around the globe.